drugset / Trial / NCT00177255
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers
Phase 2
Terminated
40 enrolled
University of Pittsburgh
Aventis Pharmaceuticals · collabRoche Pharma AG · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas.
Timeline
- Start
- 2005-04
- Primary completion
- 2008-12
- Completion
- 2008-12
Outcome
Outcome not reported
Stopped: “Roche has withdrawn support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | — |